Up a level |
Perez Nicholas, O, Lamorde, M, Kintu, K, Wang, D, Chen, T, Malaba, T, Myer, L, Waitt, C, Reynolds, H ORCID: 0000-0001-7443-4520 and Khoo, S
(2020)
COMPARATIVE QUALITY OF LIFE OUTCOMES OF DOLUTEGRAVIR-BASED OR EFAVIRENZ-BASED ANTIRETOVIRAL TREATMENT IN PREGNANCY FOR LATE PRESENTORS BETWEEN THE 3RD TRIAL-MESTER AND 48 WEEKS POSTPARTUM.
.
Orrell, C, Kintu, K, Coombs, JA, Amara, A, Myer, L, Kaboggoza, J ORCID: 0000-0001-9510-0474, Simmons, B, Else, L, Heiberg, C, Waitt, C et al (show 5 more authors)
(2018)
DolPHIN-1: Randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy.
.